Humira's Inevitable Decline: What's Waiting In The Wings?
Executive Summary
There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.
You may also be interested in...
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.
Top 10 Drugs Poised To Lose $26bn By 2020, An Infographic
Pharma companies with drugs ranked in the top 10 by global sales in 2015 will need to find an extra $26bn in revenues just to make up for the anticipated loss in sales through to 2020.
Podcast: Creating A Digital Biotech Story
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.